ES2800028T3 - Vacuna peptídica para la prevención e inmunoterapia de demencia del tipo Alzheimer - Google Patents

Vacuna peptídica para la prevención e inmunoterapia de demencia del tipo Alzheimer Download PDF

Info

Publication number
ES2800028T3
ES2800028T3 ES13878092T ES13878092T ES2800028T3 ES 2800028 T3 ES2800028 T3 ES 2800028T3 ES 13878092 T ES13878092 T ES 13878092T ES 13878092 T ES13878092 T ES 13878092T ES 2800028 T3 ES2800028 T3 ES 2800028T3
Authority
ES
Spain
Prior art keywords
peptide
vaccine
seq
nos
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13878092T
Other languages
English (en)
Spanish (es)
Inventor
Chang Yi Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Biomedical Inc
Original Assignee
United Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Biomedical Inc filed Critical United Biomedical Inc
Application granted granted Critical
Publication of ES2800028T3 publication Critical patent/ES2800028T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES13878092T 2013-03-15 2013-04-23 Vacuna peptídica para la prevención e inmunoterapia de demencia del tipo Alzheimer Active ES2800028T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/843,883 US9102752B2 (en) 2013-03-15 2013-03-15 Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
PCT/US2013/037865 WO2014143087A1 (en) 2013-03-15 2013-04-23 Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type

Publications (1)

Publication Number Publication Date
ES2800028T3 true ES2800028T3 (es) 2020-12-23

Family

ID=51527985

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13878092T Active ES2800028T3 (es) 2013-03-15 2013-04-23 Vacuna peptídica para la prevención e inmunoterapia de demencia del tipo Alzheimer

Country Status (18)

Country Link
US (4) US9102752B2 (enExample)
EP (1) EP2968485B1 (enExample)
JP (3) JP6208319B2 (enExample)
KR (2) KR101926030B1 (enExample)
CN (2) CN108794615A (enExample)
AU (3) AU2013381835A1 (enExample)
BR (1) BR112015023105A8 (enExample)
CA (1) CA2906313A1 (enExample)
DK (1) DK2968485T3 (enExample)
ES (1) ES2800028T3 (enExample)
IL (2) IL241597B (enExample)
MX (2) MX364689B (enExample)
PT (1) PT2968485T (enExample)
RU (1) RU2696566C2 (enExample)
SG (1) SG11201507669YA (enExample)
TW (1) TWI561529B (enExample)
WO (1) WO2014143087A1 (enExample)
ZA (2) ZA201507526B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
AU2015243990A1 (en) * 2014-04-07 2016-11-10 La Jolla Pharmaceutical Company Hepcidin mimetic peptides and uses thereof
EP3409130B1 (en) 2016-01-27 2020-11-25 Industry-Academic Cooperation Foundation Gyeongsang National University Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors
WO2017179646A1 (ja) * 2016-04-14 2017-10-19 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物
CN106565847B (zh) * 2016-10-26 2020-12-01 清华大学 化合物、多肽及其用途
US20210138049A1 (en) * 2017-06-16 2021-05-13 United Neuroscience Peptide immunogens from the c-terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies
AU2018355574B2 (en) * 2017-10-27 2025-09-04 United Neuroscience Tau peptide immunogen constructs
KR102745247B1 (ko) * 2017-12-11 2024-12-23 유비아이 아이피 홀딩스 아토피성 피부염의 치료 및/또는 예방을 위한 il-31의 펩타이드 면역원 및 이의 제형물
WO2019133024A1 (en) * 2017-12-31 2019-07-04 United Biomedical, Inc. Peptide immunogens and formulations thereof targeting membrane-bound ige for treatment of ige mediated allergic diseases
CA3091020A1 (en) * 2018-02-13 2019-08-22 Cedars-Sinai Medical Center Methods and systems for identification and treatment of pathological neurodegeneration and age-related cognitive decline
PE20201344A1 (es) 2018-04-10 2020-11-25 Ac Immune Sa Vacunas terapeuticas anti-abeta
WO2019213555A1 (en) * 2018-05-04 2019-11-07 Ubi Us Holdings, Llc Artificial promiscuous t helper cell epitopes that facilitate targeted antibody production with limited t cell inflammatory response
TWI676635B (zh) * 2018-06-15 2019-11-11 英屬開曼群島商聯腦科學公司 α－突觸核蛋白Ｃ端胜肽免疫原及其用於治療突觸核蛋白疾病的配方
US20210347866A1 (en) * 2018-10-01 2021-11-11 United Neuroscience Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72
WO2020132275A1 (en) * 2018-12-19 2020-06-25 Ubi Ip Holdings Artificial promiscuous t helper cell epitopes as immune stimulators for synthetic peptide immunogens
BR112021012668A2 (pt) * 2018-12-28 2021-12-28 United Biomedical Inc Imunógenos de peptídeos que possuem como alvo interleucina 6 (il-6) e formulações dos mesmos para imunoterapia de doenças impactadas pela desregulação de il-6
BR112021012906A2 (pt) * 2018-12-31 2021-12-28 United Neuroscience Ltd Imunógenos de peptídeo que têm como alvo peptídeo relacionado ao gene da calcitonina (cgrp) e formulações dos mesmos para prevenção e tratamento de enxaqueca
CN110759987B (zh) * 2019-10-29 2021-06-08 中国人民解放军军事科学院军事医学研究院 构象特异性的重组Aβ1-42样寡聚体抗原、其制备方法和应用
BR112022014616A2 (pt) * 2020-01-23 2022-12-13 United Biomedical Inc Imunógenos peptídicos de alvejamento de peptídeo ativador de adenilato ciclase pituitária (pacap) e formulações do mesmo para prevenção e tratamento de enxaqueca
US20230151069A1 (en) 2020-03-10 2023-05-18 Lifearc Cyclic Peptides
AU2021385036A1 (en) 2020-11-17 2023-06-08 ILiAD Biotechnologies, Inc. Treatment and prevention of neuropathology associated with neurodegenerative diseases
US20240159777A1 (en) * 2021-03-16 2024-05-16 Neurovision Imaging, Inc. Biofluid-Based Methods for Diagnosing Alzheimer’s Disease-Associated Conditions
US20240241122A1 (en) * 2021-05-20 2024-07-18 Denka Company Limited Anti-norovirus antibody
JP2024534269A (ja) * 2021-08-30 2024-09-18 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 神経変性疾患を治療するための方法および物質
US20250057928A1 (en) 2021-12-08 2025-02-20 Osaka University Vaccine composition for inducing anti-il-23 antibody
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
CN117586370A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도
CN115417915B (zh) * 2022-11-03 2023-02-24 北京引正基因科技有限公司 多肽载体及其应用
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途
WO2025109524A1 (en) 2023-11-22 2025-05-30 Ac Immune Sa Assays and methods for assessing vaccine preparations

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
EP0683234B2 (en) 1993-01-25 2007-06-06 Takeda Chemical Industries, Ltd. Antibody against beta-amyloid or their derivative and use thereof
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
AU7043894A (en) 1993-05-28 1994-12-20 Miriam Hospital, The Composition and method for (in vivo) imaging of amyloid deposits
WO1995011998A1 (en) 1993-10-26 1995-05-04 United Biomedical, Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI229679B (en) 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
US6025468A (en) 1998-06-20 2000-02-15 United Biomedical, Inc. Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides
ES2344189T3 (es) 1999-09-03 2010-08-20 RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. Agentes, composiciones y metodos que los utilizan utiles en el tratamiento o la prevencion de la enfermedad de alzheimer.
CN101935352A (zh) 1999-12-08 2011-01-05 智力神经系统学公司 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
US20030165481A1 (en) 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1523499A2 (en) * 2002-07-24 2005-04-20 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
US8034353B2 (en) * 2006-02-22 2011-10-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide vaccine for inducing the production of anti-amyloid β-peptide antibody
EP1996227A2 (en) * 2006-02-24 2008-12-03 CHIESI FARMACEUTICI S.p.A. Anti-amyloid immunogenic compositions, methods and uses
WO2008021296A2 (en) * 2006-08-14 2008-02-21 Thymon, L.L.C. Compositions and methods for the treatment and prophylaxis of alzheimer's disease
AT509611B1 (de) 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh Vakzin
EP2342356A4 (en) * 2008-09-29 2012-11-21 Univ Ben Gurion AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF
US9067981B1 (en) * 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8916387B2 (en) * 2010-10-28 2014-12-23 Jonas Nilsson Diagnosis and treatment of Alzheimer's disease
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type

Also Published As

Publication number Publication date
US20140271690A1 (en) 2014-09-18
CN105228644A (zh) 2016-01-06
ZA201507526B (en) 2019-12-18
JP2017226646A (ja) 2017-12-28
US9102752B2 (en) 2015-08-11
US20190194280A1 (en) 2019-06-27
KR101926030B1 (ko) 2018-12-10
IL265910A (en) 2019-06-30
TWI561529B (en) 2016-12-11
SG11201507669YA (en) 2015-10-29
AU2019246916A1 (en) 2019-10-31
IL241597B (en) 2020-07-30
KR20180132962A (ko) 2018-12-12
ZA201906683B (en) 2023-04-26
MX2015013235A (es) 2016-04-04
CN105228644B (zh) 2018-07-13
KR20150132396A (ko) 2015-11-25
JP6208319B2 (ja) 2017-10-04
EP2968485A1 (en) 2016-01-20
US20160068581A1 (en) 2016-03-10
US20180244739A1 (en) 2018-08-30
BR112015023105A2 (pt) 2017-11-21
RU2019123453A (ru) 2019-09-10
EP2968485B1 (en) 2020-03-04
AU2017203425B2 (en) 2019-07-11
RU2015142996A (ru) 2017-04-24
JP2016513638A (ja) 2016-05-16
TW201434478A (zh) 2014-09-16
AU2013381835A1 (en) 2015-10-08
JP2019196397A (ja) 2019-11-14
MX2019005268A (es) 2019-07-01
AU2017203425A1 (en) 2017-06-08
HK1212600A1 (zh) 2016-06-17
DK2968485T3 (da) 2020-06-08
MX364689B (es) 2019-05-06
EP2968485A4 (en) 2016-09-07
CN108794615A (zh) 2018-11-13
WO2014143087A1 (en) 2014-09-18
BR112015023105A8 (pt) 2018-01-23
JP6784646B2 (ja) 2020-11-11
CA2906313A1 (en) 2014-09-18
RU2696566C2 (ru) 2019-08-05
PT2968485T (pt) 2020-06-26

Similar Documents

Publication Publication Date Title
AU2017203425B2 (en) Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
BRPI0706818A2 (pt) composições, métodos e usos de imunogênicos antiamilóides
JP7563765B2 (ja) カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）を標的とするペプチド免疫原ならびに片頭痛の治療及び予防のためのそれらの配合物
BR112019026707A2 (pt) imunógenos de peptídeo da extremidade c-terminal da proteína alfa-sinucleína e formulações dos mesmos para o tratamento de sinucleinopatias
JP2023519104A (ja) 凝集膵島アミロイドポリペプチド（ｉａｐｐ）と関連する障害を予防及び治療するための、ｉａｐｐを標的とするペプチド免疫原
US20220023401A1 (en) Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type
Nitschke et al. Immunisation strategies against prion diseases: prime-boost immunisation with a PrP DNA vaccine containing foreign helper T-cell epitopes does not prevent mouse scrapie
TWI781347B (zh) 針對源自c9orf72二肽重複蛋白的胜肽免疫原結構
TWI609026B (zh) 抑制與免疫治療阿茲海默型癡呆的胜肽疫苗
RU2811687C2 (ru) Пептидная вакцина для предупреждения и иммунотерапии деменции альцгеймеровского типа
HK1212600B (zh) 預防與免疫治療阿爾茨海默型癡呆的肽疫苗
BR112020013352A2 (pt) imunógenos de peptídeo e formulações dos mesmos direcionados a ige ligada a membrana para tratamento de doenças alérgicas mediadas por ige